Delving into the Latest Updates on Zhejiang Longchuan Biomedical Technology Co., Ltd. with Synapse

Overview

Tags

Neoplasms

Immune System Diseases

Endocrinology and Metabolic Disease

Biological products

Small molecule drug

Chemical drugs

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	2
Immune System Diseases	1
Endocrinology and Metabolic Disease	1
Hemic and Lymphatic Diseases	1

Top 5 Drug Type	Count

Biological products	3
Small molecule drug	1
mRNA	1
Chemical drugs	1

Top 5 Target	Count

BTK C481S(Bruton Tyrosine Kinase C481S)	1

主要目的： 1、评价 LC004片在复发/难治性B淋巴细胞恶性肿瘤患者中的安全性和耐受性。确定LC004片的最大耐受剂量 (MTD)或最大爬坡剂量 (MAD) ，以及 II 期临床推荐剂量 (RP2D)。次要目的： 1、描述LC004片不同剂量下口服给药后的药代动力学(PK)特征。 2、描述 LC004片不同剂量下口服给药后的生物标志物(PD)变化。 3、初步评价 LC004片在复发/难治性B淋巴细胞恶性肿瘤患者中的抗肿瘤活性。 4、初步评价 LC004片在 BTK 抑制剂治疗失败（如 BTKC481S基因突变或其他获得性耐药突变）或不耐受患者中的抗肿瘤活性。

[Translation]

Primary objectives: 1. Evaluate the safety and tolerability of LC004 tablets in patients with relapsed/refractory B-lymphocyte malignancies. Determine the maximum tolerated dose (MTD) or maximum escalation dose (MAD) of LC004 tablets, as well as the recommended dose (RP2D) for Phase II clinical trials. Secondary objectives: 1. Describe the pharmacokinetic (PK) characteristics of LC004 tablets after oral administration at different doses. 2. Describe the changes in biomarkers (PD) after oral administration of LC004 tablets at different doses. 3. Preliminary evaluation of the anti-tumor activity of LC004 tablets in patients with relapsed/refractory B-lymphocyte malignancies. 4. Preliminary evaluation of the anti-tumor activity of LC004 tablets in patients who have failed BTK inhibitor treatment (such as BTKC481S gene mutations or other acquired resistance mutations) or are intolerant.

Start Date05 Apr 2023

Sponsor / Collaborator

Zhejiang Longchuan Biomedical Technology Co., Ltd.

100 Clinical Results associated with Zhejiang Longchuan Biomedical Technology Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Zhejiang Longchuan Biomedical Technology Co., Ltd.

Login to view more data

100 Deals associated with Zhejiang Longchuan Biomedical Technology Co., Ltd.

Login to view more data

100 Translational Medicine associated with Zhejiang Longchuan Biomedical Technology Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 09 May 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

4

1

IND Application

Phase 1 Clinical

1

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

WXSH-0057 ( BTK C481S )	B-Cell Lymphoma More	Phase 1
LC106	Pancreatic Cancer More	IND Application
LC201(Zhejiang Longchuan Biomedical)	-	Preclinical
LC301(Zhejiang Longchuan Biomedical)	-	Preclinical
LC202(Zhejiang Longchuan Biomedical)	-	Preclinical